



**Dr. Narinder Bhalla, BMS**

Interventional cardiologist with extensive background in clinical research and planning pragmatic, real world studies that show the value of products for patients and payers.

Nani entered the pharmaceutical industry in 2015 after 23 years in academic and private practice. He was with AstraZeneca until 2022 and joined Bristol Myers Squibb in May of 2022. He is accountable for the Worldwide Medical Strategy and evidence planning in the commercialization sector for Cardiovascular and Established Brands at BMS. He is heavily engaged with his cross functional partners in Discovery, Clinical Development, Health Economics and Outcomes Research, Commercial and Digital Health. He is intimately engaged in the BMS strategy for cardiovascular for the future and in assessing Business Development opportunities in cardiovascular. His focus is to bring BMS' innovative cardiovascular medicines to patients and to help translate BMS' science into patient care.